<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:34:06.971Z"
        cq:lastModifiedBy="msm-service"
        cq:lastRolledout="{Date}2024-02-08T16:34:06.974Z"
        cq:lastRolledoutBy="msm-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[cq:LiveRelationship,mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million"
        jcr:uuid="62aa11dd-32ba-4012-854b-948d8380997b"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-902">
        <root
            cq:lastRolledout="{Date}2024-02-08T16:34:05.820Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                cq:lastRolledout="{Date}2024-02-08T16:34:05.899Z"
                cq:lastRolledoutBy="msm-service"
                jcr:mixinTypes="[cq:LiveRelationship]"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    cq:lastRolledout="{Date}2024-02-08T16:34:05.954Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    cq:lastRolledout="{Date}2024-02-08T16:34:05.960Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:lastModified="{Date}2024-02-08T16:34:05.956Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        cq:lastRolledout="{Date}2024-02-08T16:34:05.984Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:lastModified="{Date}2024-02-08T16:34:05.980Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.009Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    cq:lastRolledout="{Date}2024-02-08T16:34:06.059Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        cq:lastRolledout="{Date}2024-02-08T16:34:06.104Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/en/News-Medien"
                        structureStart="{Long}0">
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.206Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.279Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.284Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.289Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:lastRolledout="{Date}2024-02-08T16:34:06.439Z"
                        cq:lastRolledoutBy="msm-service"
                        cq:styleIds="[1684742346871]"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.567Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2020-05-04T01:19:00.000Z">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.593Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:34:06.624Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.632Z"
                            cq:lastRolledoutBy="msm-service"
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2024-02-08T16:34:06.628Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.644Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:06.636Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-2300200p22340EDNthumbimg-placeholder_news_menarini.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.727Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:34:06.782Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    cq:lastRolledout="{Date}2024-02-08T16:34:06.788Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.794Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:06.790Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.803Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:06.798Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;ul>&#xa; &lt;li>Acquisition of Stemline establishes Menarini&amp;rsquo;s presence in the U.S. biopharmaceutical oncology&lt;br />&#xa; market&lt;/li>&#xa; &lt;li>Menarini will support further development of Stemline&amp;rsquo;s ELZONRIS&amp;reg; and enable global expansion&lt;br />&#xa; by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies&lt;/li>&#xa; &lt;li>Total potential consideration of $12.50 per share comprising $11.50 cash and $1.00 Contingent Value Right (CVR)&lt;/li>&#xa;&lt;/ul>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>FLORENCE and NEW YORK&amp;nbsp;&amp;ndash;&amp;nbsp;May 4, 2020&amp;nbsp;&amp;ndash;&amp;nbsp;Menarini Group, a privately held Italian pharmaceutical&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq:&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>transaction valued up to $677 million.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>approval. Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>(BPDCN) in adult and pediatric patients, two years or older, following the approval by the United States&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Food and Drug Administration in December 2018. ELZONRIS is a novel targeted therapy directed to the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>interleukin-3 (IL-3) receptor-Î± (CD123).&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>With the support of Menarini&amp;rsquo;s infrastructure, Stemline&amp;nbsp;will continue its efforts to develop additional&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>applications of ELZONRIS to serve the unmet needs of patients suffering from difficult to treat diseases&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>and cancers. Following its strong U.S. launch of ELZONRIS, Stemline will benefit from&amp;nbsp;Menarini&amp;rsquo;s&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>experience in bringing products to markets in Europe and emerging markets as it prepares for a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>successful international launch upon receipt of regulatory approval in ex-U.S. territories.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Elcin Barker Ergun, CEO of Menarini Group, commented,&amp;nbsp;&amp;ldquo;Stemline is an excellent fit for&amp;nbsp;Menarini,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>and pipeline of oncology assets and deliver novel therapies around the world. We look forward to uniting&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>together with the Stemline team to advance our shared mission of serving patients.&amp;rdquo;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Ivan Bergstein, M.D., Chairman, CEO and Founder of Stemline, said,&amp;nbsp;&amp;ldquo;Joining Menarini represents a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>accelerate the development of our pipeline of oncology assets. We have transitioned Stemline over the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>last several years into an established commercial-stage operation with a novel treatment, a growing&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>pipeline and a strong foundation. We are excited to be combining with a like-minded organization in&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>also allowing our shareholders to participate in the future upside of ELZONRIS&amp;rsquo;s&amp;nbsp;European launch. We&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>look forward to working closely together on our unified goal of helping and delivering hope to patients&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>worldwide.&amp;rdquo;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Transaction Terms&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 per share in cash,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>along with one non-tradeable Contingent Value Right (CVR).&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Under the terms of the non-tradeable CVR, Stemline shareholders will be paid an additional $1.00 per&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>share upon completion of the first sale for use or consumption by the general public of ELZONRIS in&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>BPDCN in any one of the following countries: United Kingdom, France, Spain, Germany, or Italy after&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>receiving approval by the European Commission of a Marketing Authorization Application (MAA), through&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>the centralized procedure, on or before December 31, 2021. There can be no assurance such approval or&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>commercialization will occur or that any contingent payment will be made.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Menarini will acquire any shares of Stemline not tendered into the tender offer through a second-step&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>merger for the same per share consideration as will be payable in the tender offer. The merger will be&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>effected as soon as practicable after the closing of the tender offer.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>The transaction has been unanimously approved by the Boards of Directors of both companies.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Stemline&amp;rsquo;s Board of Directors&amp;nbsp;recommends to shareholders of Stemline that they tender their shares into&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>the tender offer. The transaction is expected to close in the second quarter of 2020, subject to customary&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>closing conditions, including the tender of more than 50% of all shares of Stemline outstanding at the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>expiration of the offer and receipt of Hart-Scott-Rodino clearance. The terms and conditions of the tender&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>offer will be described in the tender offer documents, which will be filed with the U.S. Securities and&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Exchange Commission.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Menarini expects to fund the acquisition through existing cash resources.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Advisors&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Goldman Sachs International is acting as exclusive financial advisor and Fried, Frank, Harris, Shriver &amp;amp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Jacobson LLP is acting as legal advisor to Menarini. PJT Partners and BofA Securities are acting as&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>financial advisors and Skadden, Arps, Slate, Meagher &amp;amp; Flom LLP and Alston &amp;amp; Bird LLP are acting as&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>legal advisors to Stemline.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>About ELZONRIS&lt;/strong>&lt;strong>&amp;reg;&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>ELZONRIS&amp;reg;&amp;nbsp;(tagraxofusp), a targeted therapy directed to CD123, is approved by the U.S. Food and Drug&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>patients, two years or older, with BPDCN. For full prescribing information in the U.S., visit&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>www.ELZONRIS.com. In Europe, a marketing authorization application (MAA) is under review by the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>European Medicines Agency (EMA).&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>About BPDCN&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>BPDCN, formerly blastic NK-cell lymphoma, is an aggressive hematologic malignancy, often with&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>cutaneous manifestations, with historically poor outcomes. BPDCN typically presents in the bone marrow&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>triad of CD123, CD4, and CD56, as well as other markers. The World Health Organization (WHO) termed&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>this disease &amp;ldquo;BPDCN&amp;rdquo; in 2008; previous names included blastic NK cell lymphoma and agranular&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>CD4+/CD56+ hematodermic neoplasm. For more information, please visit the BPDCN disease&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>awareness website at&amp;nbsp;www.bpdcninfo.com.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>About Stemline&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>development and commercialization of novel oncology therapeutics. ELZONRIS&amp;reg;&amp;nbsp;(tagraxofusp), a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>treatment of adult and pediatric patients, two years and older, with BPDCN. It is the only FDA-approved&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>therapy for BPDCN in the U.S. In Europe, a marketing authorization application (MAA) is under review by&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>leukemia (AML), and additional trials and indications are planned. For more information, please visit the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>company&amp;rsquo;s website at&amp;nbsp;www.stemline.com.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>About Menarini&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>The Menarini Group is a leading international pharmaceutical company with a presence in over 100&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>countries, including a direct presence in over 70 countries. Its global platform extends throughout Europe,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Central America, Africa, the Middle East and Asia and generates over $4.2 billion in annual sales. For&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>over 125 years, Menarini has been investing in the development and commercial distribution of&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>pharmaceuticals to serve patients and physicians around the world with a full portfolio of products in the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>therapeutic areas. Menarini is also committed to oncology, with several new investigational drugs in&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>development for the treatment of a variety of tumors.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Notice to Investors and Security Holders&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>The Offer referred to in this communication has not yet commenced. The description contained in this&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>communication is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>substitute for the tender offer materials that wholly owned subsidiaries of the Menarini Group will file with&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>the Securities and Exchange Commission (the &amp;ldquo;SEC&amp;rdquo;). The solicitation and offer to buy shares of&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Stemline common stock (the &amp;ldquo;Shares&amp;rdquo;) will only be&amp;nbsp;made pursuant to an offer to purchase and related&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>tender offer materials. At the time the Offer is commenced, wholly owned subsidiaries of the Menarini&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Group will file a tender offer statement on Schedule TO and thereafter Stemline will file a&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the Offer. THE&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>IMPORTANT INFORMATION. ANY HOLDERS OF SHARES ARE URGED TO READ THESE&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>transmittal and the solicitation/recommendation statement will be made available for free at the SEC&amp;rsquo;s&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>website at www.sec.gov. Additional copies may be obtained for free by contacting Stemline. Copies of the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>documents filed with the SEC by Stemline will be available free of charge on Stemline&amp;rsquo;s internet website&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>at https://ir.stemline.com/financial-information or by contacting Stemline&amp;rsquo;s investor relations contact at +1&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>(646) 502-2307. Copies of the documents filed with the SEC by wholly owned subsidiaries of the Menarini&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Group can be obtained, when filed, free of charge by directing a request to the Information Agent for the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Offer which will be named in the tender offer materials.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>In addition to the offer to purchase, the related letter of transmittal and certain other tender offer&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>documents to be filed by wholly owned subsidiaries of the Menarini Group, as well as the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>solicitation/recommendation statement to be filed by Stemline, Stemline will also file quarterly and current&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>reports with the SEC. Stemline&amp;rsquo;s filings with the SEC are available to the public from commercial&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Forward Looking Statements&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>The information contained in this communication is as of May 4, 2020. Stemline and the wholly owned&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>subsidiaries of the Menarini Group assume no obligation to update forward-looking statements contained&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>in this communication as the result of new information or future events or developments, except as may&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>be required by law.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>This communication contains forward-looking information related to the Menarini Group, Stemline and the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>proposed acquisition of Stemline that involves substantial risks and uncertainties that could cause actual&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>results to differ materially from those expressed or implied by such statements. Forward-looking&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>statements in this document and the accompanying exhibits include, among other things, statements&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>about the potential benefits of the proposed acquisition, the anticipated contingent value right payment,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Stemline&amp;rsquo;s plans, objectives, expectations and intentions, the financial condition, results of operations and&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>business of Stemline, Stemline&amp;rsquo;s product pipeline and portfolio assets, Stemline&amp;rsquo;s ability to achieve&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>certain milestones that trigger the contingent value right payment, the anticipated timing of closing of the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>proposed acquisition and expected plans for financing the proposed acquisition. Risks and uncertainties&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>include, among other things, risks related to the satisfaction or waiver of the conditions to closing the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>proposed acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>timeframe or at all, including uncertainties as to&amp;nbsp;how many of Stemline&amp;rsquo;s stockholders will tender their&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Shares in the tender offer and the possibility that the acquisition does not close; the possibility that&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>competing offers may be made; risks related to obtaining the requisite consents to the acquisition,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>including, without limitation, the timing (including possible delays) and receipt of clearance under the Hart-&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Scott-Antitrust Improvements Act of 1976, as amended; disruption from the transaction making it more&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>difficult to maintain business and operational relationships; significant transaction costs; the uncertainties&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>inherent in research and development, including the ability to meet anticipated clinical endpoints,&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>analyses of existing clinical data and, as such, the uncertainty that the milestone for the CVR payment&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>may not be achieved in the prescribed timeframe or at all.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>A further description of risks and uncertainties relating to Stemline can be found in Stemline&amp;rsquo;s&amp;nbsp;Annual&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Report on Form 10-K for the fiscal year ended December 31, 2019, and in its subsequent Quarterly&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the SEC and available&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>at www.sec.gov and https://ir.stemline.com/financial-information.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>These forward-looking statements are based on numerous assumptions and assessments made by the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>wholly owned subsidiaries of the Menarini Group and Stemline in light of their respective experiences and&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>perceptions of historical trends, current conditions, business strategies, operating environment, future&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>developments and other factors they believe are appropriate. By their nature, forward-looking statements&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>involve known and unknown risks and uncertainties because they relate to events and depend on&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>circumstances that will occur in the future. Although it is believed that the expectations reflected in the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>forward-looking statements in this communication are reasonable, no assurance can be given that such&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>expectations will prove to have been correct and persons reading this corporate release are therefore&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>cautioned not to place undue reliance on these forward-looking statements which speak only as at the&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>date of this corporate release.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Menarini Contacts&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Media &amp;amp; Investor Relations&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Charlie Chichester / Camilla Scassellati-Sforzolini (Europe)&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Andrew Cole / Gloria Labbad (U.S.)&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Sard Verbinnen &amp;amp; Co&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Email:&amp;nbsp;menarini-svc@sardverb.com&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&lt;strong>Stemline Contacts&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Investor Relations&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Peter McDonald&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Stemline Therapeutics, Inc.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>646-502-2307&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Email:&amp;nbsp;pmcdonald@stemline.com&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Media&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Andy Brimmer / Scott Bisang&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt;&quot;>Joele Frank, Wilkinson Brimmer Katcher&lt;/p>&#xa;&#xa;&lt;p>212-355-4449&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:34:06.883Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.957Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.963Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:34:06.968Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            cq:lastRolledout="{Date}2024-02-08T16:34:06.974Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-2300200p22340EDNthumbimg-placeholder_news_menarini.jpg"/>
    </jcr:content>
</jcr:root>
